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Background: Primary malignant mediastinal germ cell tumor (PMMGCT) is rare and sometimes the prognosis of
the patients with PMMGCT is not very satisfactory.
Methods: A total of 54 patients with PMMGCT in a follow-up from 1990 to 2009. We evaluated the role of the
surgical treatment and the effect of multimodality treatment strategy for patients with PMMGCT.
Results: Fifty-two patients underwent surgical resections, while the other two patients just received
chemoradiotherapy. Among the 52 patients, 28 cases received preoperative adjuvant therapy and 24 cases
underwent surgery as initial treatment; 30 cases with complete resections, 18 cases with partial resections and 4
cases with only biopsies. There was no perioperative mortality. Histopathologic results revealed 18 cases of
seminomas and 36 cases of nonseminomatous germ cell tumors (NSGCT). The last follow-up showed that 17
patients were alive, including 11 patients with seminoma and 6 patients with NSGCT. The 5-year overall survival rate
of patients with seminomas was 87.7%. The 3-year and 5-year overall survival rates of patients with NSGCT were
47.4% and 23.0%, respectively.
Conclusions: It could be concluded that a complete surgical resection of PMMGCT after chemoradiotherapy showed
favorable long-term survival. Patients with pure seminomas have a better prognosis compared with that with NSGCT.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1676987232116837.
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Primary extragonadal germ cell tumors (GCT) are rare
and account for only 1% to 5% of all germ cell malignan-
cies [1,2]. The most common extragonadal sites are the
mediastinum and retroperitoneum [3]. These extrago-
nadal germ cell tumors histologically contain the same
components as their gonadal counterparts, but may have
different biologic behaviors, clinical characteristics and
inferior overall prognoses [4]. Furthermore, primary ma-
lignant mediastinal germ cell tumors (PMMGCT) are
rather rare and represent only 1% to 4% of all medias-
tinal tumors [5]. PMMGCT can be divided into two* Correspondence: drliuying2013@163.com
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unless otherwise stated.broad groups: seminomas and nonseminomatous germ
cell tumors (NSGCT). Pure seminoma is sensitive to
radiotherapy and the prognosis is good [6]. However,
the prognosis for NSGCT is poor [7], 5-year overall
survival rate of mediastinal NSGCT is much lower
than that of gonadal NSGCT [4,8]. For decades,
complete resection remains stable for patients with
GCT. But to the patients with PMMGCT, surgery
only has resulted in a poor prognosis. During the
last three decades, the clinical outcome of NSGCT
has been dramatically improved since the introduc-
tion of cisplatin-based chemotherapy. More and more
researchers indicate that advanced chemotherapy
regimens based on cisplatin have markedly improved
the conditions of NSGCT patients [4,8,9]. Nonethe-
less, many of such patients still have persistentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Initial symptoms and clinical data in 18 patients
with seminoma and 36 patients with nonseminomatous
germ cell tumor
Seminoma NSGCT
Symptom No. of patients (%) No. of patients (%)
Chest pain 6 (33.3) 18 (50.0)
Dyspnea 3 (16.7) 15 (41.7)
Cough 3 (16.7) 13 (36.1)
Back or shoulder pain 1 (5.6) 2 (5.6)
Hemoptysis 0 (0) 6 (16.7)
Hoarsness 0 (0) 1 (2.8)
Super vena cava syndrom 1 (5.6) 2 (5.6)
Fever 1 (5.6) 6 (16.7)
Weight loss 2 (11.1) 4 (11.1)
Asymptomatic 2 (11.1) 1 (2.8)
NSGCT: nonseminomatous germ cell tumor.
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cisplatin-based chemotherapy and conventional selv-
age chemotherapy and seldom results in a long-term
disease-free status. Therefore, surgical resection of the
residual mass after chemotherapy plays an important
role in controlling mediastinal NSGCT. This multi-
mdimensional treatment strategy serves to assess re-
sponse, to remove chemotherapy-resistant disease,
and to guide additional chemotherapy. Controversy
still exists regarding the effectiveness between surgical
resection and chemotherapy, but multidimensional
treatment has become the standard treatment for me-
diastinal NSGCT. We retrospectively reviewed our
19-year experience with 54 PMMGCT patients to




A medical records database in our department was
searched retrospectively to identify patients with PMM
GCT. Records for operations and pathology reports were
specially reviewed. Between 1990 and 2009, a total of 2152
patients with mediastinal tumors were evaluated at the
Department of Thoracic Surgery, Provincial Hospital Affil-
iated to Shandong University, China. Among these pa-
tients, there were 54 patients with continuous PMMGCT,
including 47 males and 7 females ranging from 14 to
58 years old (average age was 27 and 28.6 years old re-
spectively). Patients were further divided into seminoma
group and NSGCT group. Seminoma mixed with other
histologic type was classified as NSGCT.
Fifty-one patients had symptoms at the time of diagnosis:
chest pain in 24 cases, dyspnea in 18 cases, cough in 16
cases, fever in 7 cases, hemoptysis in 6 cases, weight loss in
6 cases, back or shoulder pain in 3 cases, superior vena cava
obstruction syndrome in 3 cases, and hoarseness in 1 case
(Table 1). All male patients had normal testicles.
All patients received standard chest X-rays and com-
puted tomography (CT) scans. It showed that all the tu-
mors were located in the anterior or anterosuperior
mediastinum. Preoperative histologic diagnosis was car-
ried out in 19 patients by fine needle biopsy guided by
ultrasound or CT. As a result, histologic evaluations re-
vealed 7 cases of mediastinal NSGCT, 12 cases of poorly
differentiated carcinoma or no diagnosable cells were
found. Serum levels of tumor markers, beta-human
chorionic gonadotropin (β-HCG) and alpha-fetoprotein
(AFP), were tested in 30 patients, among which 7 pa-
tients with elevated β-HCG, 15 patients with elevated
AFP levels, 4 patients with elevated both β-HCG and
AFP levels. Elevated serum in tumor markers (STM)
strongly indicated NSGCT. Preoperative elevated levels
of β-HCG or AFP and needle biopsy supported thediagnosis of mediastinal NSGCT. The initial clinical
diagnosis of mediastinal NSGCT was shown among 31
patients, and other patients were diagnosed as thymoma,
thymic carcinoma, and mediastinal tumor, respectively.
Methods
All statistical analyses were performed with SPSS 10.0
statistical software (SPSS, Chicago, IL, USA). Survival
rate was calculated with the Kaplan–Meier method and
difference in survival between groups was calculated by
using the log-rank test. Differences were considered to
be statistically significant when the P value was less than
0.05.
Follow-up
After discharge from the hospital, all patients in this
series were evaluated every 3-month for the first 5 years
and 6-month intervals thereafter, as well as their clinical
history, physical examination, laboratory analysis, CT
scan. There were 6 patients out of follow-up. The date
of death or last follow-up was defined as the endpoint.
Results
Among these 54 patients, 52 patients underwent surgical
resections, while the other 2 patients only received che-
moradiotherapy. Among 52 patients treated with sur-
gery, 22 patients received cisplatin-based chemotherapy
as basic treatment on the basis of a serologic diagnosis
or the needle biopsy followed by surgical resection; 6 pa-
tients received preoperative radiotherapy, which was not
very effective, then followed surgical resection thereafter;
24 patients underwent surgery as basic treatment
(Table 2). Of all these 52 patients with surgery, 30 pa-
tients were treated with complete resection, 18 patients
with partial resection and 4 patients had only biopsy.














Surgery 8 7 1 16 9 7
Chemotherapy 4 2 2 18 5 13
Radiotherapy 6 2 4 2 0 2
NSGCT: nonseminomatous germ cell tumor.
Table 3 Histologic classification of 54 patients with
primary mediastinal germ cell tumors
Tumor type No. of patients Percent (%)
Seminoma 18 33.3
York sac tumor 11 20.4
Embryonal carcinoma 3 5.55
Immature teratoma 14 25.9
Teratocarcinoma 3 5.55
Mixed germ cell tumor 5 9.3
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chemotherapy and followed by radiotherapy in 14 cases,
5 patients received radiotherapy only. The patients with
seminomas were treated with radiotherapy doses ranging
from 40 Gy to 50 Gy, while the patients with NSGCT
were treated with radiotherapy doses ranging from 50 Gy
to 54 Gy.
Surgical incisions have been grouped by the anatomic
region and extent of the tumor: median sternotomy in 26
cases, anterolateral thoracotomy in 15 cases and postero-
lateral thoracotomy in 11 cases. Pulmonary lobectomy
was performed in 4 cases and pulmonary wedge resection
in 7 cases, partial pericardial resection in 6 cases, ipsilat-
eral phrenic nerve resection in 3 cases, local chest wall
resection in 3 cases, superior vena cava reconstruction in
1 case, orthotopic great venous reconstruction with vas-
cular prosthesis placed from the remaining left innomin-
ate vein to the superior vena cava-right atria junction in
1 case. These two patients who received the artificial vas-
cular replacement have been surviving free of disease.
There were no perioperative deaths. Major postopera-
tive complications occurred in 9 patients: pulmonary in-
fection in 5 patients, phrenic nerve paralysis in 3 patients,
concurrent thrombosis of left innominate vein in 1 patient
and was successfully cured by anticoagulant therapy.
The 2 patients who didn’t receive surgery were diag-
nosed as seminomas via fine needle biopsy. Six histopath-
ologic categories of tumor were found in 52 patients who
underwent surgical resection, including 16 pure semino-
mas, 14 immature teratomas, 11 yolk sac tumors, 3 em-
bryonal cell carcinoma, 3 teratocarcinomas and 5 mixed
tumors (yolk sac tumor and immature teratoma in 2
cases, embryonal cell carcinoma and yolk sac tumor in 1
case, yolk sac tumor and seminomas in 1 case and em-
bryonal cell carcinoma and seminoma in 1 case, Table 3).
Follow-up data after surgery were available for 48 pa-
tients and 6 patients were out of follow up. At the last
follow-up, 17 patients were still alive, including 11 pa-
tients with seminoma and 6 patients with NSGCT.
Thirty-one patients died within the follow-up period, in-
cluding 27 patients with tumor-related causes and 4 pa-
tients without tumor-related causes.
Of the 16 patients with seminomas treated with
surgery, 10 patients were alive (including 8 patientswith disease-free survival for over 5 years, 1 patient with
a disease-free survival for 46 months and 1 patient with a
disease-free survival for 20 months), 5 patients died of
tumor-related or other causes and 1 patient was out of
follow-up. 2 patients with seminomas were treated only
by chemoradiotherapy, 1 patient with a disease-free sur-
vival for over 52 months and the other patient with a
disease-free survival for over 2 years, but out of follow-
up thereafter. Of the 36 patients with NSGCT, 26 pa-
tients died of tumor-related causes, 6 patients were alive
(including 4 patients with disease-free survival for over
5 years, 1 patient with a disease-free survival for over
28 months, 1 patient was alive for 4 years but with devel-
oped disease recurrence) and 4 patients were out of
follow-up. Nevertheless, all patients with NSGCT treated
with incomplete resection died or lost to follow-up
within 2 years. The median survival in the incomplete re-
section group was 7 months postoperatively (ranging
from 4 to 22 months).
The overall 5-year survival rate of the patients with
mediastinal seminoma was 87.7%. The overall 3 and 5-
year survival rates of the patients with NSGCT were
47.4% and 23.0%, respectively. The prognosis of the pa-
tients with seminoma was significantly better than that
of the patients with NSGCT (P < 0.0001, log-rank test,
Figure 1).
Discussion
The majority of GCT originates from gonad, whereas a
minority may occur in the extragonadal places such as
mediastinum, retroperitoneum and pineal gland [10].
Primary GCT of the mediastinum is relatively rare and
accounts for 10-15% of the mediastinal tumors. While
Figure 1 Kaplan-Meier curves of overall survival for 18 patients
with seminoma and 36 patients with NSGCT.
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the mediastinal tumors [5]. The exact pathogenesis of
GCT in the mediastinum is still uncertain. Retroperiton-
eal germ cell tumors are generally considered to be me-
tastases from primary gonadal lesions, whereas the
origin of primary mediastinal and pineal lesions has been
a matter of speculation. It is hypothesized that extrago-
nadal germ cell tumor (EGCT) is either a consequence
of an abnormal migration of germ cell along the midline
from the yolk sac to the embryonic gonadal ridge during
embryogenesis or result from germ cells that are dis-
tributed physiologically in the liver, bone marrow and
brain in order to provide regular functions or convey
hematologic or immunologic information [11]. Thus, the
midline structures, the anterior mediastinum especially,
are the most common occurrence site of EGCT. EGCT
can be developed as primary neoplasm in the pineal
gland, retroperitoneum, sacral area and hence they may
also be in gonadal originallyv [12].
PMMGCT are rare and occur predominantly in young
adults [5]. In our cases, male patients account for the
vast majority, the mean age at the time of diagnosis was
27 years. PMMGCT are divided into two broad groups,
seminomas and NSGCT. Seminomas retain the morph-
ology of spermatogonial germ cells and are extremely
sensitive to treatment by radiation as well as chemo-
therapy [10,13]. NSGCT includes yolk sac tumor, embry-
onal carcinoma, choriocarcinoma, immature teratoma,
terato- carcinoma and mixed tumors with both differen-
tiated and undifferentiated elements [13]. They are, as a
group, still sensitive to chemotherapy, although they are
less sensitive to radiationtherapy than seminomas [10].
Seminomas are the most common mediastinal malignant
GCT [9]. Cesar A et al. reported that primary mediastinalseminomas accounted for approximately 37% of all medi-
astinal GCT [14] and Clamon and Economon et al. re-
ported that one-half of malignant GCT are seminomas
[15,16]. In our series, seminomas occupy 33.3% of all ma-
lignant tumors. A higher incidence of NSGCT was found,
this may attribute to the cases of immature teratoma.
Cesar A reported that yolk sac tumor is the most common
NSGCT of the mediastinum, accounting for 12% of all
GCT in this location [17]. We retrospectively reviewed 54
cases of continuous PMMGCT in our hospital, including
11 yolk sac tumors.
PMMGCT is often prone to be misdiagnosed, because
of their nonspecific clinical symptoms. The presenting
symptoms are cough, chest pain, hemoptysis, and/or dys-
pnea which are second to compression of adjacent tis-
sues. In addition, some patients presented without any
symptoms, and the diagnosis was made by a routine
physical or radiographic examinations. Sometimes, the
diagnosis of PMMGCT may be confused with thymoma,
thymic carcinoma and Hodgkin’ disease. In this case, a
careful clinical history and the serum levels of β-HCG
and AFP may be helpful in making accurate diagnosis.
The elevated serum markers of β-HCG and/or AFP will
ultimately favor a diagnosis of NSGCT. Takeda S et al.
reported that approximately 90% of their patients with
NSGCT had elevated STM levels [5]. In our series, the
patients with elevated β-HCG and/or AFP are all histologic
NSGCT. Some patients were treated with chemotherapy
according to the elevated levels of STM. It has also been
reported that the STM levels can be survival predictive
[18]. Furthermore, the definite diagnosis of PMMGCT re-
lies on pathological examinations. Sometimes, PMMGCT
are morphologically indistinguishable from some other
malignant tumors, but immunohistochemical studies will
ultimately lead to the correct diagnosis. For decades, the
preoperative cytologic examination by percutaneous fine-
needle biopsy has become the common method to diag-
nose the mediastinal mass. But sometimes, the needle
biopsy samples are too small to do immunohistochemical
studies, so the preoperative needle biopsy is usually unre-
liable. Furthermore, it also increases the possibility of
needle track implantation. In our series, 19 patients had
needle biopsy, only 7 patients with accurate diagnoses. In
this regard, biopsy via mediastinoscopy or thoracoscopy
is required for the final diagnosis of highly suspected
PMMGCT,but the risk also increases. In addition, GCT
could have a mixed histology, so the diagnosis of semi-
noma based on small biopsy specimens should be consid-
ered clinically as well as histopathologically.
Associated syndromes, such as hematologic malig-
nancies (leukemia or myelodysplastic syndrome) have
already been reported in some patients with PMMGCT
[19]. In addition, NSGCT is occasionally associated with
klinfelter syndrome [20]. However, the reasons for these
Liu et al. Diagnostic Pathology 2014, 9:33 Page 5 of 6
http://www.diagnosticpathology.org/content/9/1/33associations in mediastinal NSGCT remain to be clari-
fied. We didn’t notice such associated syndromes in any
of our cases.
In the last two decades, several authors have reported
the effectiveness of cisplatin-based chemotherapy, which
has become the standard therapy for PMMGCT [4,8,9].
The role of surgical resection has been changed into
multidimensional therapy for PMMGCT. Recently, the
treatment of PMMGCT with cisplatin-based chemother-
apy followed by surgical resection of residual disease is
currently one of the most successful approaches of
multidimensional therapy [18].
We currently believe that most of the patients with
PMMGCT can not be diagnosed definitely before oper-
ation, but only can be assured by intraoperative biopsy or
resected specimens. Primary surgical resection is still the
most important way. Particularly to the patients with small
and resectable tumors without any invasion, we should
first perform thoractomy for radical resection, followed by
postoperative chemotherapy and/or radiotherapy. In fact,
patients really benefit from surgery when complete exci-
sion can be performed, but partial resection has not been
demonstrated beneficial [21]. In our cases, partial resec-
tion or partial response to chemotherapy resulted in a sub-
sequent rapid progression of the disease. Therefore,
complete resection must be the surgical target in every
case. But to the patients with locally advanced tumors,
which involved adjacent organs and couldn’t be com-
pletely resected, systematic chemotherapy could be rec-
ommended to reduce the tumor mass and prevent
metastases outside the mediastinum, if necessery, selvage
resection could be performed thereafter.
It is well known that seminomas are radiosensitive tu-
mors [6]. Primary or adjuvant radiations for mediastinal
seminomas have been effective in the local control of
the tumors [4,9,15]. Based on our observations, it ap-
pears that complete surgical resection of mediastinal
seminomas followed by local radiation and cisplatin-
based combination chemotherapy would be the very
effective treatment for these patients. Nevertheless,
NSGCT are relatively resistant to radiotherapy which is
not recommended. To the patients of NSGCT with large
mediastinal mass, aggressive cisplatin-based chemother-
apy followed by resection of the residual tumor has be-
come the best approach to improve the survival of these
patients. This approach avoids demanding or incomplete
resections and unnecessary resections. Thoracic surgery
was typically delayed for 4 weeks after chemotherapy,
which allowed the patient, in particular, to have the bone
marrow to recover.
Most of the patients with PMMGCT have large medias-
tinal mass, even extensive involvement of the adjacent or-
gans. Not infrequently, the mediastinal mass is adherent
to the mediastinal surfaces of the cardiac chambers,surgery is technically demanding. Nonetheless, we should
perform aggressive resection in the patients with PM
MGCT if anatomically feasible, including, if necessary,
the artificial vascular replacement,great vein and alterna-
tive cardiac chamber resection. In our cases, the two pa-
tients who had been performed the artificial vascular
replacements had a better prognosis. Although the suc-
cess of chemotherapeutic regimens in PMMGCT is im-
portant, skilled thoracic surgery is an equally important
component for successful multidimensional therapy. In
this series, patients with PMMGCT who underwent ini-
tial tumor resection had higher complete response rate
and disease-free survival compared with those who had
only biopsy or partial resection. But the role of initial
tumor resection needs further evaluation in prospective
studies.
Wright CD et al. had emphasized the importance of
normalization of STM before surgical extirpation of re-
sidual disease in patients with NSGCT [22]. The patients
whose STM remained elevated after first-line chemo-
therapy should receive second-line chemotherapy. But
Kesler KA et al. [20] reported that operable patients
should undergo surgical extirpation of residual disease
after first-line chemotherapy, regardless of STM status.
In our series, the STM levels were not measured in
some patients before or after surgery,more experiences
would be required to evaluate the role of surgery in pa-
tients with an elevated and increasing STM before surgi-
cal resection.
In conclusion, the prognosis of patients with semino-
mas is significantly better than that of patients with
NSGCT. The results of multidimensional therapy for
PMMGCT depend on both successful chemotherapy
and surgery. The complete resection of the tumor is im-
portant, with wide surgical margins including great vein
and adjacent structures, if necessary. New therapeutic
strategies are currently being studied in the treatment of
the patients with PMMGCT to minimize operative mor-
bidity and to improve the long-term survival equivalent
to that of testicular NSGCT.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YL, ZW and YY conceived the study idea and designed the study. YL, ZW
and YY reviewed the literature and performed statistical analyses. YL, ZW,
ZMP and YY drafted the manuscript. YL and YY reviewed and edited the
manuscript. All authors read and approved the final manuscript.
Received: 23 December 2013 Accepted: 3 February 2014
Published: 19 February 2014
Reference
1. Iyoda A, Hiroshima K, Yusa T, Toyozaki T, Fujisawa T, Ohwada H: The
primary mediastinal growing teratoma syndrome. Anticancer Res 2000,
20:3723–3726.
Liu et al. Diagnostic Pathology 2014, 9:33 Page 6 of 6
http://www.diagnosticpathology.org/content/9/1/332. Hainsworth JD, Greco FA: Extragonadal germ cell tumors and
unrecognized germ cell tumors. Semin Oncol 1992, 19:119–127.
3. Ganjoo KN, Rieger KM, Kesler KA, Sharma M, Heilman DK, Einhorn LH:
Results of modern therapy for patients with mediastinal
nonseminomatous germ cell tumors. Cancer 2000, 88:1051–1056.
4. Nichols CR: Mediastinal germ cell tumors. Clinical features and biologic
correlates. Chest 1991, 99:472–479.
5. Takeda S, Miyoshi S, Ohta M, Minami M, Masaoka A, Matsuda H: Primary
germ cell tumors in the mediastinum: a 50-year experience at a single
Japanese institution. Cancer 2003, 97:367–376.
6. Kersh CR, Constable WC, Hahn SS, Spaulding CA, Eisert DR, Jenrette JM,
Marks RD, et al: Primary malignant extragonadal germ cell tumors.
An analysis of the effect of the effect of radiotherapy. Cancer 1990,
65:2681–2685.
7. Kay PH, Wells FC, Goldstraw P: A multidisciplinary approach to primary
nonseminomatous germ cell tumors of the mediastinum. Ann Thorac
Surg 1987, 44:578–582.
8. Nichols CR, Saxman S, Williams SD, Loehrer PJ, Miller ME, Wright C, Einhorn
LH: Primary mediastinal nonseminomatous germ cell tumors. A modern
single institution experience. Cancer 1990, 65:1641–1646.
9. Dulmet EM, Macchiarini P, Suc B, Verley JM: Germ cell tumors of the
mediastinum. A 30-year experience. Cancer 1993, 72:1894–1901.
10. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 1997,
337:242–253.
11. Friedman NB: The function of the primordial germ cell in extragonadal
tissues. Int J Androl 1987, 10:43–49.
12. Johnson DE, Laneri JP, Mountain CF, Luna M: Extragonadal germ cell
tumors. Surgery 1973, 73:85–90.
13. Ulbright TM: Germ cell neoplasms of the testis. Am J Surg Pathol 1993,
17:1075–1091.
14. Moran CA, Suster S, Przygodzki RM, Koss MN: Primary germ cell tumors of
the mediastinum: II. Mediastinal seminomas–a clinicopathologic and
immunohistochemical study of 120 cases. Cancer 1997, 80:691–698.
15. Clamon GH: Management of primary mediastinal seminoma. Chest 1983,
83:263–267.
16. Economou JS, Trump DL, Holmes EC, Eggleston JE: Management of
primary germ cell tumors of the mediastinum. J Thorac Cardiovasc Surg
1982, 83:643–649.
17. Moran CA, Suster S, Koss MN: Primary germ cell tumors of the
mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma,
and combined nonteratomatous germ cell tumors of the mediastinum–a
clinicopathologic and immunohistochemical study of 64 cases. Cancer
1997, 80:699–707.
18. Kesler KA, Rieger KM, Hammoud ZT, Kruter LE, Perkins SM, Turrentine MW,
Schneider BP, et al: A 25-year single institution experience with surgery
for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac
Surg 2008, 85:371–378.
19. Nichols CR, Hoffman R, Einhorn LH, Williams SD, Wheeler LA, Garnick MB:
Hematologic malignancies associated with primary mediastinal
germ-cell tumors. Ann Intern Med 1985, 102:603–609.
20. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J,
et al: Hematologic disorders associated with primary mediastinal
nonseminomatous germ cell tumors. J Natl Cancer Inst 2000, 92:54–61.
21. Jain KK, Bosl GJ, Bains MS, Whitmore WF, Golbey RB: The treatment of
extragonadal seminoma. J Clin Oncol 1984, 2:820–827.
22. Wright CD, Kesler KA, Nichols CR, Mahomed Y, Einhorn LH, Miller ME, Brown
JW: Primary mediastinal nonseminomatous germ cell tumors. Results of
a multimodality approach. J Thorac Cardiovasc Surg 1990, 99:210–217.
doi:10.1186/1746-1596-9-33
Cite this article as: Liu et al.: Management of the primary malignant
mediastinal germ cell tumors: experience with 54 patients. Diagnostic
Pathology 2014 9:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
